Clinical trials: New Onset Type-1 Diabetes
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.
- Trial name
- DAWN (NCT03794973)
- Testing
- TOL-3021
- Where
- United States
- Sponsor
- Tolerion, Inc.
Diabetes Mellitus, Type 1
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.
- Trial name
- NCT04598893
- Testing
- Teplizumab
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 188 people
- Sponsor
- Provention Bio, a Sanofi Company